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Abstract
Ex vivo expansion of hematopoietic stem and progenitor cells (HSPC) is a promising ap-
proach to improve insufficient engraftment after umbilical cord blood stem cell transplanta-
tion (UCB-SCT). Although culturing HSPC with hematopoietic cytokines results in robust
proliferation, it is accompanied with extensive differentiation and loss of self-renewal capaci-
ty. Wnt signaling has been implicated in regulating HSPC fate decisions in vivo and in pro-
moting HSPC self-renewal by inhibition of differentiation, but the effects of Wnt on the ex
vivo expansion of HSPC are controversial. Here, we demonstrate that exogenous Wnt3a
protein suppresses rather than promotes the expansion of UCB-derived CD34+ cells in
serum free expansion cultures. The reduced expansion was also observed in cultures initi-
ated with Lin-CD34+CD38lowCD45RA-CD90+ cells which are highly enriched in HSC and
was also observed in response to activation of beta-catenin signaling by GSK3 inhibition.
The presence of Wnt3a protein during the culture reduced the frequency of multilineage
CFU-GEMM and the long-term repopulation ability of the expanded HSPC. These data sug-
gest that Wnt signaling reduces expansion of human HSPC in growth factor-driven expan-
sion cultures by promoting differentiation of HSPC.
Introduction
Allogeneic hematopoietic stem cell transplantation is an important part of treatment for pa-
tients suffering from hematological disorders, including leukemia, myelodysplastic syndromes,
and aplastic anemia. However, many patients lack a suitable sibling or human leucocyte anti-
gen (HLA) matched unrelated donor. Because of its rapid availability and less stringent match-
ing criteria[1], umbilical cord blood (UCB) is an important alternative source for
hematopoietic stem and progenitor cells (HSPC). However, UCB-derived HSPC significantly
differ from bone marrow- and peripheral blood-derived HSPC quantitatively and qualitatively.
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UCB grafts contain a relatively low number of HSPC which are relatively more primitive, re-
sulting in impaired engraftment and a delayed hematopoietic recovery[1–5], during which pa-
tients are at increased risk for severe complications, including infections and bleeding. Several
approaches have been pursued to improve engraftment after UCB transplantation, including
the ex vivo expansion of HSPC.
HSC are defined by their self-renewal capacity and the ability to generate all different he-
matopoietic lineages. Although in vivo studies demonstrated that HSPC expand after trans-
plantation[6], robust ex vivo expansion of long-term repopulating HSC remains a challenge.
Culturing HSPC with different combinations of hematopoietic cytokines such as stem cell
factor (SCF), Fms-related tyrosine kinase 3 ligand (Flt3L), thrombopoietin (TPO) and
granulocyte-macrophage colony-stimulating factor (GM—CSF) resulted in massive expansion
of committed HPC which is accompanied by a loss or at best maintenance of primitive HSC
with long-term repopulation ability.[7–11]. Additional signals are needed to support the ex-
pansion of primitive HSC in ex vivo culture systems. Several novel factors, such as the immobi-
lized Notch-ligand Delta1, copper chelator tetra-ethylenepentamine (TEPA) and signals
derived from mesenchymal stromal cells, were identified that may affect self-renewal of HSC
and inhibit differentiation, thereby having the potential to improve ex vivo expansion proto-
cols[12–14]. In addition, numerous promising factors have been tested in a pre-clinical setting,
including developmental regulators such as fibroblast growth factor signaling, insulin-like
growth factor, Angiopoietin-like proteins and Pleiotrophin and chemical modulators like all-
trans retinoic acid, stemregenin1 and prostaglandin E2 (reviewed by Walasek et al.[15]).
The Wnt/beta-catenin signaling pathway regulates cell fate decisions in many developmen-
tal processes in embryo and adult. Stimulation of cells with Wnt signaling proteins induces the
stabilization and accumulation of the signal transducer protein beta-catenin, which then local-
izes into the nucleus where it regulates target gene expression (reviewed by Clevers et al.[16]).
When combined with other growth factors, Wnt proteins can promote self-renewal in several
types of stem cells, such as mammary, intestinal and embryonic stem cells[17–20]. Several
studies, using different approaches to inhibit the Wnt signaling pathway, showed that Wnt sig-
naling is pivotal for normal HSC function in mouse[21–23]. In addition, some reports show
that treatment with recombinant Wnt3a protein or overexpression of activated beta-catenin
enhances the self-renewal capacity of mouse HSC ex vivo[24–26]. These studies offer hope that
Wnt signals may be of use in the expansion of human UCB-derived HSPC. However, other
studies show that constitutive activation of beta-catenin blocks multilineage differentiation[27]
and that active beta-catenin induces apoptosis in HSPC[28, 29].
In this study we investigate the effect of Wnt signals on growth factor-driven ex vivo expan-
sion of human HSPC. We show that Wnt3a signaling reduces growth factor driven expansion
of human HSPC by promoting differentiation.
Material and Methods
Cord blood processing, CD34+ cell selection and HSC sorting
Umbilical cord blood was collected in several hospitals using Stemcare/CB collect blood bag
system (Fresenius Kabi Norge AS) containing citrate phosphate dextrose (CPD) as an anticoag-
ulant. Approval for collection was obtained from the Medical Ethical Committee of the Eras-
mus University Medical Centre (MEC-2009–410) and written informed consent from the
mother was obtained prior to donation of the cord blood. Within 48 hours after collection,
mononuclear cells were isolated using ficoll (Lymphoprep, Fresenius Kabi Norge AS). CD34+
cells were isolated with double positive immunomagnetic selection using Magnetic Activated
Cell Sorting (MACS) technology according instructions of the manufacturer (Miltenyi Biotech
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GmBH, Bergisch Gladbach, Germany). MACS-selected CD34+ cells were either used directly
in experiments or stained with anti-Lin-FITC, anti-CD38-PerCP-Cy5.5, anti-CD90-PE (all
from eBioscience, Vienna, Austria), anti-CD34-PE-Cy7, anti-CD45RA-APC-H7 (both from
BD Biosciences, San Jose, CA, USA) and DAPI (Sigma-Aldrich, St Louis, MO, USA) after
which viable DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cells, highly enriched for hemato-
poietic stem cells (HSC)[30], were sorted using BD FACSAria Cell Sorting System (BD Biosci-
ences, San Jose, CA, USA).
Expansion cultures
Selected CD34+ cells and sorted DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cellswere cul-
tured in serum free Glycostem Basic Growth Medium (GBGM, Glycostem, Oss, The Nether-
lands) or StemSpan Serum-Free Expansion Medium (SFEM, Stemcell Technologies, Grenoble,
France) supplemented with 20 μg/ml low molecular weight heparin (Abbott, Wiesbaden, Ger-
many) and the early acting growth factors SCF (50 ng/ml, Cellgenix, Freiburg, Germany), Flt3L
(50 ng/ml, Cellgenix, Freiburg, Germany) and TPO (50 ng/ml, Cellgenix, Freiburg, Germany)
(from now on referred to as ‘SFT medium’) with or without the addition of 250 ng/ml purified
Wnt3a unless indicated otherwise. Cells were cultured in a volume of 1 ml in 24-well plate at a
concentration of 105/ml at 37°C in 5% CO2. Every 2 to 3 days, wells were split or half of the me-
dium was refreshed. In some experiments, we used GSK3β inhibitor CH99021 (1 μM, Stem-
gent, Cambridge, MA, USA) as an alternative activator of the canonical Wnt pathway.
Frizzled8CRD (Fr8CRD, which blocks the binding of Wnt3a to its receptor) was produced as
described[31] and used at a concentration of 15 μg/ml. Wnt3a was combined in some experi-
ments with the Aryl hydrocarbon Receptor (AhR) antagonist StemRegenin1 (SR1, 1 μM, Cella-
gen Technology, San Diego, CA, USA).
Purification of Wnt3a and preparation of liposomal Wnt3a
Wnt3a-conditioned medium was collected from Drosophila S2 cells grown in suspension cul-
ture. Wnt3a was further purified using Blue Sepharose affinity and gel filtration chromatography
as described[24]. Liposomes containing DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine),
DMPG (1,2-dimyristoyl-sn-glycero-3-phospho-rac-glycerol) (both Lipoid AG) and Cholesterol
(Sigma-Aldrich, St Louis, MO, USA) at a 10:1:10 molar ratio were prepared by extrusion method.
PurifiedWnt3a was mixed with liposomes at a 1:7.5 ratio to achieve a total concentration of
7–10 μg/ml of Wnt3a. After mixing, theWnt liposomes were incubated for at least one hour on
the roller coaster at 4°C. Next, CHAPS was removed from theWnt liposomes by dialysis at least
three times in PBS 1 hour each, using dialysis membrane with molecular weight cut-off of
10 kDa at 4°C. TheWnt liposomes were stored at 4°C. Activity of purifiedWnt3a protein and li-
posomal Wnt3a was determined in a luciferase reporter assay (see below).
Luciferase reporter assay
Mouse LSL cells, which express luciferase in response to TCF promoter binding, were routinely
cultured at 37°C and 5% CO2 in culture medium composed of DMEM (Invitrogen, Life Tech-
nologies, Bleiswijk, The Netherlands), 10% FCS, and 1% Penicillin/Streptomycin. For the activ-
ity assays, Wnt3a reagents at a concentration of 250 ng/ml were incubated in culture medium
without FCS for various periods of time at 37°C in U-bottom 96-well plates. These media were
then transferred to F-bottom 96-well plates containing LSL cells, which were plated the day be-
fore at a density of 25,000 cells/well. After overnight incubation with the indicated Wnt re-
agents, relative luciferase units were measured with Glomax multiplate reader.
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Flowcytometry
At serial time points in culture, absolute numbers of viable CD34+ cells were determined by a
single platform flowcytometric assay, using anti-CD45-FITC, anti-CD34-PE, DAPI and a cali-
brated number of Stem-Count Fluorospheres (all from Beckman Coulter, Fullerton, CA, USA).
Within the CD34+ population, the frequency of DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-
cells was determined using the antibody panel as described above for the sorting of these cells.
Absolute numbers of DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cells were determined by
multiplying the absolute number of CD34+ cells obtained in the single platform analysis by the
percentage of DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cells within the CD34+ cell popula-
tion. Flowcytometric analysis was performed using a BD FACSCanto (BD Biosciences, San
Jose, CA, USA) and data was analyzed using FlowJo software (Tree Star Inc, Ashland, OR,
USA).
Transplantation of human hematopoietic cells into NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice
This study was carried out in accordance to the Dutch law on Animal Welfare and Experi-
ments. The protocol was approved by the Committee on the Ethics of Animal Experiments of
the Erasmus University Medical Centre Rotterdam, The Netherlands. Intrabone transplanta-
tions were performed under isoflurane anesthesia. All animals were housed in groups in indi-
vidually ventilated cages. Food and water were available ad libitum.
NSG mice were sublethally irradiated (3 Gy) and subsequently transplanted with the proge-
ny generated from 1,00E+05 UCB-derived CD34+ cells cultured in our SFT medium, with or
without the addition of 250 ng/ml Wnt3a for 7 days. Each group contained 5 mice. Engraft-
ment was assessed every 2 weeks starting at 3 weeks after transplantation by flowcytometric
analysis of the peripheral blood, using a flowcytometric panel including anti-mouseCD45-
eFluor450, (eBioscience, Vienna, Austria) and anti-humanCD45-APC-Cy7 (BioLegend, Lon-
don, UK). Mice were considered engrafted when human CD45 levels were higher than 0.1%.
At 17 weeks after transplantation, the mice were sacrificed by cervical dislocation and cells
from femurs were analysed.
Results
Wnt3a reduces growth factor-driven expansion of UCB derived CD34+
cells
To assess whether Wnt signals affect expansion of human HSPC in culture, UCB-derived
CD34+ cells were cultured in serum-free medium supplemented with SCF, Flt3L and TPO
(SFT medium) with or without purified Wnt3a protein. After 14 days, no significant change in
total nucleated cell expansion was observed in response to Wnt3a protein (Fig. 1A, p = 0.74).
However, Wnt3a accelerated the decline in the frequency of CD34+ cells that was observed dur-
ing culture (Fig. 1B, p<0.001 for both 7 and 14 days of culture and Fig. 1C), resulting in a sig-
nificantly reduced expansion of CD34+ cells after 2 weeks of culture (Fig. 1D). In addition, we
observed a higher frequency of cells expressing lineage markers after 14 days of culture in the
presence of Wnt3a protein compared with SFT medium only (Fig. 1E, p<0.05). Next, we as-
sessed the functionality of the cultured CD34+ cells by performing colony forming unit (CFU)
assays. The presence of Wnt3a during culture reduced the frequency of multi-lineage CFU-
GEMM (granulocyte, erythrocyte, monocyte, megakaryocyte), while no effect was seen in the
frequency of lineage committed BFU-E (Burst Forming Unit-Erythrocyte) and CFU-GM
(granulocyte, macrophage) (Fig. 1F). The reduction in frequency of most immature CFU and
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Fig 1. ExogenousWnt3a reduces growth factor-driven expansion of CD34+ cells.UCB-derived CD34+ cells were cultured in serum free SFT medium
with or without the addition of Wnt3a. Cells were analyzed using flow cytometry at 7 and 14 days of culture. Shown are (A) the total nucleated cell expansion
compared to input (n = 8), (B) the frequency of CD34+ cells within the TNC population during culture (n = 8), (C) expression of CD45 and CD34 after 14 days
of culture in SFT with (lower panel) or without (upper panel) Wnt3a (representative experiment out of 8), (D) the expansion of CD34+ cells compared to input
(n = 8) and (E) the frequency of cells expressing lineage markers after 7 and 14 days of culture (n = 6). (F) Frequency of CFU-GEMM, BFU-E and CFU-GM in
Wnt3a Reduces Growth Factor-Driven HSPC Expansion
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the higher frequency of lineage positive cells suggest that exogenous Wnt3a protein promotes
rather than inhibits growth factor-driven differentiation of CD34+ cells in expansion cultures.
Next, we evaluated the dose-response relationship of Wnt signaling on the in vitro expansion
of CD34+ cells. At the lowest concentration of 25 ng/ml, Wnt3a had no effect on the expansion
of CD34+ cells relative to control SFT cultures (Fig. 1G). On the other hand, the highest con-
centration of 2500 ng/ml Wnt3a protein resulted in a decline of total cell number (not shown)
and a complete loss of CD34+ cells (Fig. 1G). The effect of Wnt3a on the repopulating ability of
the expanded CD34+ cells was assessed by transplantation of the expanded population of cells
into sublethally irradiated NSG mice after 7 days of culture. All transplanted mice showed en-
graftment (defined as>0.1% human CD45+ cells in the peripheral blood at 7 weeks after trans-
plantation). However, the kinetics of human chimerism development in peripheral blood
appeared delayed when cells were cultured in the presence of Wnt3a (Fig. 1H). Lower levels of
human chimerism were also observed in the bone marrow of mice 17 weeks after transplanta-
tion of cells cultured in the presence of Wnt3a (Fig. 1I, 36.9% versus 10.1% respectively,
p<0.05). This indicates that Wnt3a protein reduces the long-term repopulation ability of cul-
tured CD34+ cells.
Wnt3a reduces growth factor-driven expansion of HSC
CD34+ cells constitute a heterogeneous population, including only a minor fraction of the
most immature HSC subset. Wnt3a may act differentially on primitive HSC and CD34+ cells
with committed progenitor properties A putative differentiation-inhibiting effect of Wnt3a on
HSC may be obscured by a differentiation-inducing effect on the large population of commit-
ted progenitor cells in culture. To study the effects of Wnt3a on the most immature HSC sub-
set, we expanded Lin-CD34+CD38low CD45RAlowCD90+-cells, highly enriched for HSC[30] in
the presence or absence of Wnt3a. A similar effect of Wnt3a was observed on the expansion of
the sorted Lin- CD34+ CD38low CD45RAlow CD90+-cells. A robust total nucleated cell expan-
sion, approximately 100-fold, was observed regardless of the presence of Wnt3a (Fig. 2A).
However, Wnt3a again accelerated the decline in the frequency of CD34+ cells (Fig. 2B, p<0.05
and p<0.01 for 7 and 14 days of culture, respectively) and led to a significantly reduced expan-
sion of CD34+ cells (Fig. 2C, p<0.01). Moreover, Wnt3a strongly reduced the number of
Lin-CD34+ CD38low CD45RAlow CD90+-cellsobtained after culture, while these cells were
maintained in the absence of Wnt3a (Fig. 2D). These data suggest that Wnt3a inhibits the ex-
pansion of both multilineage committed progenitors and HSC.
Prolongation of Wnt3a activity does not result in increased expansion of
CD34+ cells
Purified Wnt3a has been shown to have a half-life that is considerably shorter than 24 hours
upon dilution in serum free media[32]. Thus, daily addition of Wnt3a protein to cell cultures
would result in intermittent rather than continuous activation of the pathway. A possible ex-
planation for our observations of reduced HSPC expansion in response to daily Wnt3a addi-
tion is that these intermittent pulses are unable to inhibit HSC differentiation. At the same
time, Wnt signals may promote the differentiation of more mature CD34+ cells, leading to an
250 CD34+ cells cultured for 2 weeks in SFT or SFT+Wnt3a (n = 2, 3 dishes per experiment). (G) CD34+ cell expansion compared to SFT medium after
14 days of culture with different dosages of Wnt3a (n = 2). (H) Levels of human chimerism at several time points after transplantation with the progeny of
105 CD34+ cells cultured for 7 days in SFT or SFT+Wnt3a medium (n = 5 mice per group). (I) Levels of human chimerism in bone marrow 17 weeks after
transplantation with the progeny of 105 CD34+ cells cultured for 7 days in SFT or SFT+Wnt3a medium (n = 5 mice per group). * p<0.05, ** p<0.01,
*** p<0.001
doi:10.1371/journal.pone.0119086.g001
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overall reduction of HSPC. The stability of Wnt3a protein can be increased by association with
liposomes[33, 34], and we therefore tested whether such stabilized Wnt ligands were able to
prevent the decline in HSPC that we observed in response to regular Wnt3a protein. We com-
pared the stability of purified Wnt3a protein and of Wnt3a protein associated with liposomes
by incubating the proteins in serum free medium at 37°C and assessing the remaining Wnt-ac-
tivity at several time points by a luciferase reporter assay. Whereas purified Wnt3a lost its activ-
ity within 8 hours, liposomal Wnt3a retained significant activity after 24 hours (Fig. 3A).
Despite this increased stability however, liposomal Wnt3a induced a 3.3-fold decline of CD34+
cell expansion (Fig. 3B), similar to purified Wnt3a. In conclusion, prolongation of Wnt3a activ-
ity does not result in increased expansion of CD34+ cells.
Enhanced differentiation of CD34+ cells is dependent on activation of the
canonical Wnt pathway
Binding of Wnt3a to its receptor can be blocked with the Wnt antagonist Fz8CRD, a soluble
domain of the Wnt receptor that sequesters Wnt proteins[31]. To demonstrate that the
Fig 2. Wnt3a reduces growth factor-driven expansion of HSC.UCB-derived DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cells were sorted out of CD34-
selected cells and were cultured in SFT medium with or without Wnt3a. Flowcytometric analysis was performed at day 7 and 14. Depicted are (A) the total
nucleated cell expansion in SFT and SFT+Wnt3a medium at 7 and 14 days of culture (n = 4), (B) the CD34+ cell frequency during culture (n = 4), (C) the fold
expansion of CD34+ cells at day 7 and 14 of culture (n = 4) and (D) the total number of DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cellsat input and after
14 days of culture in SFT or SFT+Wnt3a medium (n = 4). * p<0.05, ** p<0.01
doi:10.1371/journal.pone.0119086.g002
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observed effects of Wnt3a were indeed dependent on binding to its receptor on HSPC, CD34+
cells were cultured with or without Wnt3a and/or Fz8CRD. The negative effect of exogenous
Wnt3a on the expansion of CD34+ cells and the decline in frequency of CD34+ cells during cul-
ture was reversed by the addition of Fz8CRD. (Fig. 4A and 4B). An alternative way to activate
the canonical Wnt pathway is by inhibiting glycogen synthase kinase 3β (GSK3β) which results
in stabilization of the cytoplasmic β-catenin pool and subsequent transfer to the nucleus. To
confirm that activation of the canonical Wnt pathway by exogenous Wnt3a underlies the in-
hibitory effects of Wnt3a on the expansion of CD34+ cells we used a synthetic GSK3β-inhibitor
(CHIR99021). Addition of CHIR99021 supressed the expansion of CD34+ cells (Fig. 4C) to a
similar extend as purified Wnt3a protein (Fig. 1D). Collectively these data show that the re-
duced expansion of CD34+ cells is due to binding of Wnt3a protein to its receptor on HSPC
and subsequent activation of canonical Wnt pathway.
Wnt3a inhibits expansion of CD34+ cells driven by the Aryl hydrocarbon
receptor antagonist Stemregenin1
The Aryl hydrocarbon Receptor (AhR) is implicated to play a role in the proliferation and dif-
ferentiation of HSPC. AhR-KO mice have increased number of LSK cells in the bone marrow
and these LSK are hyperproliferative[35] and hematopoietic progenitors of donor mice treated
with the AhR agonist TCDD show impaired competitive engraftment[36]. In addition, the
AhR antagonist StemRegenin1 (SR1) has been shown to effectively enhance the expansion of
human HSPC[37, 38]. We included SR1 in our cultures as a positive control for enhancing
growth factor-driven CD34+ cell expansion and in addition, to evaluate putative cooperative
effects of the Wnt and AhR signalling pathways. Expectedly, SR1 indeed promoted CD34+ cell
expansion to a similar extent as reported before[37], indicating the suitability of our SFT medi-
um, while Wnt3a reduced CD34+ cell expansion (Fig. 5). Addition of both Wnt3a and SR1 re-
sulted in an increased expansion compared to Wnt alone, but a reduced expansion compared
to SR1 alone (Fig. 5, p<0.01 and p<0.05 respectively), showing that even in the presence of
AhR pathway inhibition, Wnt3a suppresses the expansion of CD34+ cells.
Fig 3. Liposomal Wnt3a reduces expansion of CD34+ cells. (A) Purified Wnt3a and liposomal Wnt3a were
incubated for 0, 8, and 24 hours at 37°C in cell culture media, and transferred to LSL cells. RemainingWnt
activity was assayed by luminescence measurements. Activity plot displays average increase of
luminescence over incubation time relative to background (n = 10). (B) CD34+ cell expansion in SFT medium
with or without liposomal Wnt3a after 7 days of culture (n = 1).
doi:10.1371/journal.pone.0119086.g003
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Fig 4. Wnt3a-mediated inhibition of HSPC expansion is due to activation of the canonical Wnt3a pathway. (A) Expansion of CD34+ cells after 7 and
14 days of culture in SFT, SFT+Wnt3a, SFT+Fr8CRD and SFT+Wnt3a+Fr8CRD (n = 2). (B) CD34+ cell frequency within the TNC population during these
cultures (n = 2). (C) CD34+ cell expansion in SFT and SFT+CHIR99021 after 7 and 14 days of culture (n = 2).
doi:10.1371/journal.pone.0119086.g004
Fig 5. Wnt3a inhibits SR1-enhanced CD34+ cell expansion.UCB-derived CD34+ HSPCwere cultured for
14 days in SFT or SFTSR1 medium with or without the addition of Wnt3a. Flowcytometric analysis was
performed at day 14. Depicted is the CD34+ cell expansion after 14 days of culture (n = 5). * p<0.05,
** p<0.01
doi:10.1371/journal.pone.0119086.g005
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Discussion
The effects of Wnt signaling on human HSPC proliferation, differentiation and survival are
still poorly understood. In this study, we show that Wnt3a protein suppresses rather than pro-
motes growth factor-driven expansion of UCB-derived CD34+ cells in serum-free expansion
cultures. Wnt3a induced accelerated differentiation of both HSC and multipotent progenitors,
resulting in the production of more differentiated cells. The reduced expansion of human
HSPC, appeared to be dependent on activation of the canonical Wnt signaling pathway upon
binding of Wnt3a to its receptor at the cell surface.
Our findings compare well to those by Nemeth et al., who observed a decrease in expansion
of mouse LSKI (Lineage negative, Sca-1+, c-kit+, IL-7Rα-) cells after culture in serum-free me-
dium containing SCF, Flt3L andWnt3a compared to culture conditions with growth factors
only. In addition, they showed no enhanced repopulation capacity of Wnt3a-cultured LSKI
cells compared to control-cultured cells[25]. Earlier, several studies showed that overexpres-
sion of beta-catenin in HSC resulted in a functional defect of hematopoiesis and loss of repopu-
lating activity[27, 39]. These results are in line with our observations of enhanced
differentiation of HSPC upon stimulation of the canonical Wnt pathway. However, Malhotra
et al. reported that overexpression of activated beta-catenin may expand the pool of HSC, both
phenotypically and functionally in long term cultures[40]. In addition, overexpression of the
Wnt inhibitor Dickkopf-related protein 1 (Dkk1) was shown to significantly impair the self-
renewal capacity of adult HSC[21, 22]. How to reconcile these contradictory results? Although
at first sight contradictory, the many differences in types of cultures, cells growth factors added
may explain some of the observed differences.
Willert et al. and Reya et al. earlier showed that purified Wnt3a induced proliferation, while
inhibiting differentiation of HSC in growth-factor based cultures of mouse LSKT (Lineage neg-
ative, Sca-1+, c-kit+, Thy-1.1lo)[24, 26]. However, they used cells derived from BCL2 transgenic
mice. The BCL2 anti-apoptotic signal in HSPC may counteract possible apoptotic signals in-
duced by Wnt3a signaling. Moreover, they used serum, which may supply additional signals
that allow canonical Wnt signaling to exert a differentiation inhibitory effect or a more pro-
nounced effect on self-renewal. It would compare well to several other studies[28, 41], which
show that the presence of additional factors is required to balance the activated Wnt pathway.
Trowbridge et al. showed enhanced long-term repopulation after treating mice with a
GSK3beta inhibitor, which regulates the canonical Wnt pathway and several other pathways as
well[41]. Perry et al. showed that the combination of a PTEN deletion and activation of beta-
catenin results in enhanced self-renewal and expansion of HSC[28]. Another important path-
way involved in HSC self-renewal and inhibition of differentiation is the pathway initiated by
the aryl hydrocarbon Receptor (AhR). It is now well established that AhR-KO mice have in-
creased number of LSK cells in the bone marrow and these LSK are hyperproliferative[35],
while hematopoietic progenitors of donor mice treated with AhR agonist TCDD show im-
paired competitive engraftment[36]. In addition, the AhR antagonist StemRegenin1 (SR1) pro-
motes expansion of human hematopoietic stem cells[37, 38]. We evaluated whether combined
inhibition of the AhR pathway and activation of the Wnt pathway would result in enhanced ex-
pansion of HSPC. However, Wnt signaling also reduced the expansion of CD34+ HSPC in the
presence of the aryl hydrocarbon receptor antagonist SR1. Another important factor that may
affect the response of HSPC to Wnt signaling is the level of oxygenation. Expansion cultures
are usually performed at normoxic levels. However, it is well established that the response of
HSPC to hematopoietic cytokines is different under normoxic and hypoxic conditions, which
mimics the in situ bone marrow environment[42]. The effect of stimulation of the canonical
Wnt pathway on HSC expansion may be modulated by the level of oxygenation, which was
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already shown for the effect of the Wnt4-dependent pathway on the functional capacities of
mesenchymal stem cells[43].
Apart from other cytokines and pathways involved, the dose and timing of Wnt activation
might play an important role. Our data show that both intermittent pulses of Wnt3a and more
continuous exposure to Wnt3a have a similar negative effect on the expansion of CD34+ cells
in serum-free expansion cultures. Luis et al reported that Wnts are tightly regulated in a dose-
dependent fashion[44], which may affect their biological activity. Thereby, varying results (ex-
erted via the canonical Wnt pathway) may result from different levels of Wnt signaling, such as
can be achieved in different experimental conditions. The optimal level of Wnt signaling for
HSC was suggested to be only slightly increased over normal physiological values, while higher
levels resulted in impaired engraftment potential of HSC fashion[44].
Collectively, we show that exogenous Wnt3a proteins reduces the expansion of human
HSPC in serum-free growth factor-driven HSPC expansion cultures by promoting their differ-
entiation without apparently affecting their proliferation or survival. It cannot be excluded that
additional signals, such as the induction of a hypoxic cellular response, are needed for a possi-
ble positive effect of canonical Wnt signaling on HSPC expansion. Future studies may address
the fragile balance between canonical Wnt signaling and other pathways to determine whether
combined activation of Wnt signaling and other signaling pathways may promote human
HSPC expansion.
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